Last updated on November 2017

A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer


Brief description of study

A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer

Detailed Study Description

The purpose of this research study is to evaluate the effectiveness and safety of one dose of rAd-IFN with Syn3 (InstiladrinTM) given to patients with High Grade BCG-unresponsive non-muscle invasive bladder cancer. Instiladrin™ is a gene transfer agent and is being developed for transfer of the Interferon a-2b gene in into the bladder.

Clinical Study Identifier: TX15170

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Candice Fortuna

The Urology Center of Colorado
Denver, CO USA
  Connect »